Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page updated its Locations section to add sites across multiple states including Colorado, District of Columbia, Louisiana, Maryland, Massachusetts, Michigan, Missouri, New York, Ohio, Pennsylvania, Tennessee, Texas, and Washington, and removed the previous state locations; the revision tag also updated to v3.3.3.SummaryDifference1%
- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check40 days agoChange DetectedThe page revision updated from v3.2.0 to v3.3.2, indicating a minor update to the study record. This change does not modify the study details or enrollment information.SummaryDifference0.0%
- Check47 days agoChange DetectedThe government funding and operating status notice was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check61 days agoChange DetectedNo additions or deletions were detected on the page; the content appears unchanged between versions.SummaryDifference0.4%
- Check90 days agoChange DetectedMajor update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.SummaryDifference4%
- Check97 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%
Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.